Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulio Cavalli

Showing results (51-60 of 136) with videos related to

Pageof 14
Sort By:
Autoimmunity Reviews|December 22, 2014
Giant cell arteritis restricted to the limb arteries: An overlooked clinical entityAlvise Berti, Corrado Campochiaro, Giulio Cavalli, et al.
Seminars in Arthritis and Rheumatism|December 19, 2020
Drug retention rates of biological agents in adult onset Still's diseaseCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
The Lancet. Rheumatology|October 6, 2021
Cutaneous vasculitis following COVID-19 vaccinationGiulio Cavalli, Serena Colafrancesco, Giacomo De Luca, et al.
Frontiers in Immunology|June 19, 2018
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester DiseaseAlessandro Tomelleri, Giulio Cavalli, Giacomo De Luca, et al.
RMD Open|August 31, 2023
Developing a framework for the implementation of recommendations for lifestyle factors for people with RMDs across Europe: assessment of current materials and implementation needsJavier Rodríguez-Carrio, Giulio Cavalli, James Gwinnutt, et al.
Frontiers in Immunology|April 9, 2021
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac InvolvementGiacomo De Luca, Giulio Cavalli, Corrado Campochiaro, et al.
Frontiers in Pharmacology|January 14, 2021
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the PandemicGiulio Cavalli, Nicola Farina, Corrado Campochiaro, et al.
Annals of the Rheumatic Diseases|August 2, 2020
Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by FerraccioliEmanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 25, 2022
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case seriesCorrado Campochiaro, Alessandro Tomelleri, Giulio Cavalli, et al.
Arthritis Research & Therapy|February 27, 2019
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's diseaseGiulio Cavalli, Alessandro Tomelleri, Giacomo De Luca, et al.
Pageof 14

Showing results (51-60 of 136) with videos related to

Sort By:
Pageof 14
Autoimmunity Reviews|December 22, 2014
Giant cell arteritis restricted to the limb arteries: An overlooked clinical entityAlvise Berti, Corrado Campochiaro, Giulio Cavalli, et al.
Seminars in Arthritis and Rheumatism|December 19, 2020
Drug retention rates of biological agents in adult onset Still's diseaseCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
The Lancet. Rheumatology|October 6, 2021
Cutaneous vasculitis following COVID-19 vaccinationGiulio Cavalli, Serena Colafrancesco, Giacomo De Luca, et al.
Frontiers in Immunology|June 19, 2018
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester DiseaseAlessandro Tomelleri, Giulio Cavalli, Giacomo De Luca, et al.
RMD Open|August 31, 2023
Developing a framework for the implementation of recommendations for lifestyle factors for people with RMDs across Europe: assessment of current materials and implementation needsJavier Rodríguez-Carrio, Giulio Cavalli, James Gwinnutt, et al.
Frontiers in Immunology|April 9, 2021
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac InvolvementGiacomo De Luca, Giulio Cavalli, Corrado Campochiaro, et al.
Frontiers in Pharmacology|January 14, 2021
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the PandemicGiulio Cavalli, Nicola Farina, Corrado Campochiaro, et al.
Annals of the Rheumatic Diseases|August 2, 2020
Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by FerraccioliEmanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 25, 2022
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case seriesCorrado Campochiaro, Alessandro Tomelleri, Giulio Cavalli, et al.
Arthritis Research & Therapy|February 27, 2019
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's diseaseGiulio Cavalli, Alessandro Tomelleri, Giacomo De Luca, et al.
Pageof 14